

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3594660

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SCHRODINGER, LLC	08/03/2015
RECEIVING PARTY DATA		
Name:	PHARMACYCLICS LLC	
Street Address:	995 EAST ARQUES AVENUE	
City:	SUNNYVALE	
State/Country:	CALIFORNIA	
Postal Code:	94085	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14790978
CORRESPONDENCE DATA		
Fax Number:	(201)587-0715	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2014875800	
Email:	info@kjiplaw.com	
Correspondent Name:	KLAUBER & JACKSON LLC	
Address Line 1:	25 EAST SPRING VALLEY AVENUE	
Address Line 2:	SUITE 160	
Address Line 4:	MAYWOOD, NEW JERSEY 07607	
ATTORNEY DOCKET NUMBER:	3446-1-001N	
NAME OF SUBMITTER:	DAVID A. JACKSON	
SIGNATURE:	/David A. Jackson/	
DATE SIGNED:	10/30/2015	
Total Attachments: 2		
source=3446_1_001N_executed_Assignment_Schroedinger_PCYC#page1.tif		
source=3446_1_001N_executed_Assignment_Schroedinger_PCYC#page2.tif		

PATENT ASSIGNMENT

Docket Numbers 00501US, 00501WO AND
00501WO2 (3446-1-001N, 3446-1-001PCT, and
3446-1-001PCT2)

WHEREAS, **SCHRÖDINGER, LLC, a Delaware Limited Liability Company**, having a place of business at **120 West 45th St, 17th Floor, NY, NY 10036**, (hereinafter "Assignor"), owns right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

INHIBITORS OF BRUTON'S TYROSINE KINASE

☐ for which a United States patent application is executed on even date herewith;
☒ for which application serial numbers 14/790,978, PCT/US2015/38937 AND PCT/US2015/38986 were filed on July 2, 2015 in the United States Patent and Trademark Office; (hereinafter "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, **Pharmacylics, LLC, a Delaware Limited Liability Company**, having a place of business at **995 East Arques Avenue, Sunnyvale, CA 94085**, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by Assignor's Inventor(s), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has sold, assigned, transferred, and conveyed and does hereby sell, assign, transfer and convey unto said Assignee, Assignor's entire right, title and interest (a) in and to said Inventions; (b) in and to said Application(s), including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any or said application covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuation or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of New York, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

SCHRÖDINGER, LLC, a Delaware Limited Liability Company

Date: AUG 3, 2015

By: [Signature]
Name/Title: Randy Fand
President

Date: AUG 3, 2015

Witness: [Signature]
Name: Yvonne Tran

RECEIVED AND AGREED TO BY ASSIGNEE: **Pharmacyclics LLC,**

Date: 18 Aug 2015 By: [Signature]
Elaine C. Stracker, Ph.D., J.D.
Vice President, Legal

State/Commonwealth of CALIFORNIA)
County of SANTA CLARA)

On 18 AUGUST 2015 before me, ESTHER CAMPBELL, Notary (Name/Title of Notary) personally appeared Elaine C. Stracker (Name of Signer) who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that s/he executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State/Commonwealth of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: [Signature] (Notary Seal)

